Comparative Pharmacology
Head-to-head clinical analysis: VASOXYL versus VAZCULEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASOXYL versus VAZCULEP.
VASOXYL vs VAZCULEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction and increased blood pressure.
Vazculep is a direct-acting vasoconstrictor that stimulates alpha-adrenergic receptors in vascular smooth muscle, causing peripheral vasoconstriction and increased blood pressure.
Intravenous bolus: 0.1-0.2 mg per dose; intravenous infusion: 0.1-0.2 mg/min; intramuscular or subcutaneous: 0.5-1 mg per dose.
5 mg IV bolus followed by 2.5 mg/hour continuous IV infusion; titrate to mean arterial pressure ≥65 mmHg. Maximum infusion rate: 40 mg/hour.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; clinically relevant for dosing intervals in hypotension management.
Terminal elimination half-life is 12 hours. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 24 hours. Dose adjustment is recommended for CrCl <30 mL/min.
Primarily renal excretion as unchanged drug and metabolites (phenylephrine is deaminated by MAO). Approximately 80-85% excreted in urine within 24 hours; negligible biliary/fecal elimination.
Renal excretion of unchanged drug accounts for 70% and fecal/biliary excretion accounts for 30%. Approximately 15% of the dose is excreted as glucuronide conjugate in urine.
Category C
Category C
Vasopressor
Vasopressor